ALB and type 2 diabetes mellitus: The 2023 European Society of Cardiology (ESC) guidelines state that finerenone (Recommended for 1A) should be added to ACEIs or ARBs in patients with T2DM complicated by an eGFR > 60 mL/min/1.73 m2 with a urinary albumin-to-creatinine ratio (uACR) ≥ 300 mg/g, or an eGFR of 25 to 60 mL/min/1.73 m2 with a uACR ≥ 30 mg/g, to further reduce cardiovascular events and renal failure (156).